Similarly, multiple oncogenic fusions involving FGFR3, RET or ALK were identified as common resistance mechanisms to the third-generation EGFR TKI osimertinib in EGFR-mutant NSCLC patients27. This evidence concerns the gene FGFR3 and non-small cell lung carcinoma.